Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Brief Summary: A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.


Options:
A: Arm Label: Arm I (platinum-based chemotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Procedure: Computed Tomography, Procedure: Echocardiography Test, Drug: Gemcitabine, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (olaparib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm III (olaparib, cediranib maleate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Drug: Cediranib Maleate, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Cediranib Maleate; Assigned to Arm(s): Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Echocardiography Test; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Multigated Acquisition Scan; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate)
B: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2
D: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets

Answer: D